Nasopharyngitis (Common Cold) Drugs in Development, 2022 Update – Featuring Adare Pharma Solutions, Charleston Labs, Eurofarma Labs, Pfizer, SaNOtize R&D Corp, and Tris Pharma Among Others – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Nasopharyngitis (Common Cold) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering.
This pipeline guide provides an overview of the Nasopharyngitis pipeline landscape.
Companies Involved in Therapeutics Development
- Adare Pharma Solutions
- Charleston Laboratories Inc
- Eurofarma Laboratorios SA
- Firebrick Pharma Pty Ltd
- Pfizer Inc
- SaNOtize Research & Development Corp
- SSP Co Ltd
- Tris Pharma Inc
Drug Profiles
- (Acetaminophen + Fexofenadine + Phenylephrine)
- Guaifenesin ER
- Hydrocodone bitartrate + Undisclosed drug
- IMP-1088
- NORS-1002
- ORB-110
- Povidone iodine
- Small Molecule to Inhibit MAPK13 for Asthma and Cold
- ST-HT
- TRN-123
- TRN-124
- TRN-125
Report Highlights
This pipeline guide Nasopharyngitis (Common Cold) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngitis (Common Cold) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 1, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
- The pipeline guide reviews pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered
Introduction
Report Coverage
Overview
Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Companies Involved in Therapeutics Development
Drug Profiles
Dormant Projects
Discontinued Products
Product Development Milestones
Featured News & Press Releases
For more information about this report visit https://www.researchandmarkets.com/r/y2c52u
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
